随时间推移报告“严重”与“非严重”药物不良反应的趋势：法国药物警戒数据库中的一项研究。
Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database.
机构信息
CHU Toulouse, Service de Pharmacologie Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Toulouse, F-31059, France.
出版信息
Br J Clin Pharmacol. 2012 Jul;74(1):201-4. doi: 10.1111/j.1365-2125.2012.04185.x.
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Several factors are known to influence spontaneous reporting of adverse drug reactions (ADRs). Among them, 'seriousness' of the reaction is one of the most important. • However, evolution in the reporting of 'serious'vs.'non-serious' ADRs over time for the same drug remains unknown.
WHAT THIS STUDY ADDS
• Spontaneous reports mainly involve 'non-serious' ADRs during the first years of marketing and 'serious' ADRs later, particularly for drugs with non-hospital use.
AIM
To investigate trends in spontaneous reporting to the French Pharmacovigilance system of 'serious' (SADRs) and 'non-serious' (NSADRs) adverse drug reactions over time.
METHODS
Annual SADR : NSADR ratios were calculated for each drug and their evolution tested with linear trend tests.
RESULTS
Among the 39 new active substances commercialized in France in 2000, 16 had sufficient data to perform linear trend tests. An increasing linear relation was found for five widely prescribed drugs, a non-significant increasing trend for eight others, i.e. drugs mostly used in hospitals.
CONCLUSION
ADR reports mainly concern NSADRs during first years of marketing. Reports of SADRs are proportionally more frequent later.
摘要
已知本主题的相关信息
有几个因素已知会影响药物不良反应（ADR）的自发报告。其中，反应的“严重程度”是最重要的因素之一。
然而，对于同一种药物，随着时间的推移，“严重”和“非严重”ADR 报告的演变情况仍不清楚。
本研究的新增内容
- 自发报告主要涉及药物上市初期的“非严重”ADR，以及后期的“严重”ADR，特别是对于非医院使用的药物。
目的
调查法国药物警戒系统中“严重”（SADR）和“非严重”（NSADR）药物不良反应随时间的自发报告趋势。
方法
计算每种药物的年度 SADR：NSADR 比值，并通过线性趋势检验测试其演变。
结果
在 2000 年法国上市的 39 种新活性物质中，有 16 种有足够的数据进行线性趋势检验。五种广泛使用的药物呈明显的线性关系，另外八种药物呈非显著的上升趋势，即主要在医院使用的药物。
结论
ADR 报告主要在上市初期涉及非严重不良反应。随着时间的推移，严重不良反应的报告比例更高。
相似文献
1
Trends of reporting of 'serious'vs. 'non-serious' adverse drug reactions over time: a study in the French PharmacoVigilance Database.随时间推移报告“严重”与“非严重”药物不良反应的趋势：法国药物警戒数据库中的一项研究。
Br J Clin Pharmacol. 2012 Jul;74(1):201-4. doi: 10.1111/j.1365-2125.2012.04185.x.
2
First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.法国首次报告大流行流感疫苗（H1N1）接种后患者不良反应：患者和医务人员报告的比较。
Drug Saf. 2012 Oct 1;35(10):845-54. doi: 10.1007/BF03261980.
3
Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France.主动式区域药物警戒系统与国家自发报告在收集关于可疑超说明书用药行为安全性数据方面的比较：以法国巴氯芬与酒精依赖为例
Drug Saf. 2017 Mar;40(3):257-262. doi: 10.1007/s40264-016-0489-7.
4
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.对2004年9月至2016年12月尼日利亚VigiFlow数据库中严重药品不良反应报告的回顾性分析
Pharmaceut Med. 2019 Apr;33(2):145-157. doi: 10.1007/s40290-019-00267-2.
5
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.评估患者向英国“黄卡计划”报告药物不良反应的情况：文献回顾、描述性和定性分析以及问卷调查。
Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200.
6
A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006.2003 年和 2006 年法国两次热浪期间药物不良反应的对比研究。
Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):285-8. doi: 10.1002/pds.2307. Epub 2011 Dec 8.
7
Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).向法国药物警戒系统报告的自发药品不良反应趋势（1986 - 2001年）
Drug Saf. 2005;28(8):731-40. doi: 10.2165/00002018-200528080-00007.
8
Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.2003年夏季法国热浪期间70岁以上患者的药物不良反应：来自法国药物警戒数据库的一项研究
Pharmacoepidemiol Drug Saf. 2006 Oct;15(10):735-40. doi: 10.1002/pds.1284.
9
Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.评价向墨西哥国家药物警戒中心报告的疑似药物不良反应报告的完整性：一项横断面时期患病率研究。
Drug Saf. 2012 Oct 1;35(10):837-44. doi: 10.1007/BF03261979.
10
Adverse drug reactions to self-medication: a study in a pharmacovigilance database.自我药疗的药物不良反应：一项基于药物警戒数据库的研究
Fundam Clin Pharmacol. 2015 Oct;29(5):517-20. doi: 10.1111/fcp.12140. Epub 2015 Aug 24.
引用本文的文献
1
Tyrosine Kinase Inhibitors and Interstitial Lung Disease: A Disproportionality Analysis Using the European Post-marketing EudraVigilance Database.酪氨酸激酶抑制剂与间质性肺病：使用欧洲上市后药物警戒数据库进行的不成比例性分析
Drugs Real World Outcomes. 2025 Sep 2. doi: 10.1007/s40801-025-00515-9.
2
Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela™).全球首个用于犬骨关节炎的单克隆抗体的药物警戒报告：贝迪维单抗（Librela™）的案例研究
Front Vet Sci. 2025 Apr 24;12:1558222. doi: 10.3389/fvets.2025.1558222. eCollection 2025.
3
Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs.与抗肥胖药物相关的严重不良事件报告趋势分析。
Pharmacol Res Perspect. 2025 Apr;13(2):e70080. doi: 10.1002/prp2.70080.
4
High-risks drug adverse events associated with Cetirizine and Loratadine for the treatment of allergic diseases: A retrospective pharmacovigilance study based on the FDA adverse event reporting system database.西替利嗪和氯雷他定治疗过敏性疾病的高风险药物不良事件：一项基于美国食品药品监督管理局不良事件报告系统数据库的回顾性药物警戒研究
Clin Transl Allergy. 2024 Sep;14(9):e12392. doi: 10.1002/clt2.12392.
5
Use of the Capture-Recapture Method to Estimate the Frequency of Community- and Hospital-Acquired Drug-Induced Acute Kidney Injuries in French Databases.在法国数据库中使用捕获-再捕获法估计社区获得性和医院获得性药物性急性肾损伤的发生率。
Front Pharmacol. 2022 Jul 5;13:899164. doi: 10.3389/fphar.2022.899164. eCollection 2022.
6
..
World Allergy Organ J. 2022 Jul 2;15(7):100658. doi: 10.1016/j.waojou.2022.100658. eCollection 2022 Jul.
7
A systematic review and network meta-analysis of the safety of early interventional treatments in rheumatoid arthritis.类风湿关节炎早期介入治疗安全性的系统评价和网络荟萃分析。
Rheumatology (Oxford). 2021 Oct 2;60(10):4450-4462. doi: 10.1093/rheumatology/keab429.
8
Amoxicillin-induced crystal nephropathy: A nationwide French pharmacovigilance databases study.阿莫西林诱发的晶体性肾病：一项基于法国全国药物警戒数据库的研究
Br J Clin Pharmacol. 2020 Nov;86(11):2256-2265. doi: 10.1111/bcp.14328. Epub 2020 Jun 17.
9
Occurrences and Outcomes of Immune Checkpoint Inhibitors-Induced Vitiligo in Cancer Patients: A Retrospective Cohort Study.免疫检查点抑制剂诱导的癌症患者白癜风的发生和结局：一项回顾性队列研究。
Drug Saf. 2020 Feb;43(2):111-117. doi: 10.1007/s40264-019-00875-6.
10
Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures.在欧洲经济区（EEA）实施风险最小化措施前后，报告了静脉铁剂给药后的严重过敏反应。
Drug Saf. 2020 Jan;43(1):35-43. doi: 10.1007/s40264-019-00868-5.
本文引用的文献
1
Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect.确定血管紧张素II受体阻滞剂类四种药物的不良事件报告模式：重温韦伯效应。
Pharmacoepidemiol Drug Saf. 2008 Sep;17(9):882-9. doi: 10.1002/pds.1633.
2
The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database.数据库知识发现技术在药品上市后安全性监测中的应用：以世界卫生组织数据库为例
Fundam Clin Pharmacol. 2008 Apr;22(2):127-40. doi: 10.1111/j.1472-8206.2007.00552.x. Epub 2008 Feb 1.
3
Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.用于评估药物不良反应的药物警戒：价值、组织与方法
Joint Bone Spine. 2006 Dec;73(6):629-32. doi: 10.1016/j.jbspin.2006.09.002. Epub 2006 Oct 12.
4
Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.利用自愿提交给美国食品药品监督管理局的上市后不良事件报告对韦伯效应进行复制。
Pharmacotherapy. 2004 Jun;24(6):743-9. doi: 10.1592/phco.24.8.743.36068.
5
Mechanism of action of adverse drug reactions: an overview.药物不良反应的作用机制：概述
Pharmacoepidemiol Drug Saf. 1997 Oct;6 Suppl 3:S43-50. doi: 10.1002/(sici)1099-1557(199710)6:3+<s43::aid-pds308>3.3.co;2-u.
6
Application of data mining techniques in pharmacovigilance.数据挖掘技术在药物警戒中的应用。
Br J Clin Pharmacol. 2004 Feb;57(2):127-34. doi: 10.1046/j.1365-2125.2003.01968.x.
7
The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles.韦伯曲线陷阱：强制引入对报告率和报告的不良反应特征的影响。
Pharm World Sci. 2003 Dec;25(6):260-3. doi: 10.1023/b:phar.0000006518.22231.ea.
8
Adverse event reporting with selective serotonin-reuptake inhibitors.选择性5-羟色胺再摄取抑制剂的不良事件报告
Ann Pharmacother. 2003 Oct;37(10):1387-91. doi: 10.1345/aph.1C522.
9
Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions.医生关于药品不良反应自发报告系统的知识与态度。
J Clin Epidemiol. 2002 Sep;55(9):945-50. doi: 10.1016/s0895-4356(02)00450-x.
10
Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited.非甾体抗炎药自发不良事件报告的时间模式：重温韦伯效应
Drug Saf. 2001;24(3):233-7. doi: 10.2165/00002018-200124030-00006.
Zotero 插件